{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.53","value":"1078.1"},{"groupId":"OG001","spread":"61.83","value":"992.80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"description":"Progression-free survival was defined as time from date of randomization to death from any cause or one of the following events:\n\n* progression to stage II or III according to Salmon \\& Durie classification\n* skeletal related events (pathologic fracture, initiation of radiotherapy or surgery on bone, spinal cord compression or hypercalcemia)\n* unequivocal progression of osteolytic lesions (at least a 20% increase in the largest diameter of one existing osteolytic lesion which is measured in at least one dimension as 20 mm with conventional techniques), determined radiologically.","dispersionType":"Standard Error","groups":[{"description":"Participants received intravenous infusion of Zoledronic acid every 4 weeks for 48 weeks, and calcium and Vitamin D daily.","id":"OG000","title":"Zoledronic Acid (ZOL446)"},{"description":"No Treatment with study medication.","id":"OG001","title":"Control"}],"paramType":"MEAN","populationDescription":"Intent to Treat Population","reportingStatus":"POSTED","timeFrame":"48 months","title":"Days of Progression Free Survival","type":"PRIMARY","unitOfMeasure":"Days"}